United States: PAMA Final Rule

Last Updated: July 7 2016
Article by Thomas Barker and Brian P. Carey

Market Based Payment for Clinical Diagnostic Laboratory Tests


On June 17, 2016 the Centers of Medicare & Medicaid Services (CMS) issued the long awaited Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule. The Final Rule implements the laboratory test payment provisions of the Protecting Access to Medicare Act of 2014 (PAMA), enacted into law on April 1, 2014. Section 216 of PAMA added section 1834A to the Social Security Act, which requires significant revisions to the payment methodologies for clinical diagnostic laboratory tests (CDLTs) paid under the Clinical Laboratory Fee Schedule (CLFS). Under section 1834A, certain clinical laboratories are required to report private payor payment rates and corresponding test volumes. PAMA directs CMS to establish parameters for payment rate reporting by June 30, 2015 and requires the market-based payment system to start on January 1, 2017. However, in the Final Rule, CMS has delayed the data collection and reporting requirements. The market-based payment rates for most laboratory tests currently paid on the CLFS will now take effect on January 1, 2018. The agency is planning to issue sub-regulatory guidance on additional topics, such as: a list of specific HCPCS codes for which laboratories must report data, the Advanced Diagnostic Laboratory Test (ADLT) application process, and manner and form for electronic reporting of private payer data. CMS estimates $390 million in savings in 2018, $1.7 billion over five years, and $3.9 billion over ten years.

Implementation Timeline

  • January 1, 2016 – June 30, 2016: Initial data collection period for CDLTs.
  • July 18, 2016: Advisory Panel on Clinical Laboratory Diagnostic Tests Meeting on ADLT Designation and Coding.
  • Prior to January 1, 2017: CMS will issue sub-regulatory guidance on the list of specific HCPCS codes for which laboratories must report data, and the application for ADLT designation.
  • Prior to January 1, 2017: Assign unique HCPCS codes and publish payment rates for existing ADLTs and existing FDA-cleared or approved CDLTs.
  • January 1, 2017 – March 31, 2017: Initial data reporting period for CDLTs.
  • September 2017: CMS publishes preliminary CLFS rates for CY 2018.
  • November 2017: CMS posts final CY 2018 CLFS rates.
  • January 1, 2018: Market-based payment rates effective.
    • ADLTs are on an annual cycle of collection, reporting, and payment
    • The CDLTs cycle takes place every three years.
  • January 1, 2018: Payment system for new ADLTs effective.
    • Three quarters at Actual List Charge.
    • Private payor data collected during Q1 and Q2 must be reported by the end of Q2.
  • January 1, 2019 – June 30, 2019: Next Data Collection Period for CDLTs.

Market-Based Payment System

A. Collection and Reporting

Who has to collect and report?

PAMA requires "applicable laboratories" to report to CMS, and defines an "applicable laboratory" as a laboratory that receives a majority of its Medicare revenues during the data collection period from the CLFS or the Physician Fee Schedule. In the proposed rule, CMS defined applicable laboratories based on an entity's IRS Taxpayer Identification Number (TIN). In the Final Rule, in response to comments, CMS modified the definition of an applicable laboratory to be at the National Provider Identifier (NPI) level, not the TIN level. CMS stated that this would allow the inclusion of hospital outreach laboratories in the definition of "applicable laboratories."

CMS originally proposed a low expenditure threshold for applicable laboratories, which would exclude a laboratory from the definition of an applicable laboratory if it received less than $50,000 in CLFS revenues during a collection period. CMS reduced the low expenditure threshold from $50,000 to $12,500 in the Final Rule in part due to the shortening of the data collection period. Additionally, in response to comments, CMS exempted laboratories offering and furnishing ADLTs from the expenditure threshold with respect to those ADLTs. Applicable information about ADLTs can be reported from a laboratory that failed to meet the expenditure threshold, but information about other CDLTs cannot be.

PAMA authorized CMS to establish a low volume threshold in addition to a low expenditure threshold. However, CMS declined to exercise this authority at this time. Additionally, CMS rejected commenters' suggestion that it establish a physician office laboratory (POL) dependent test revenue threshold that would allow POLs that did not reach the low expenditure threshold to report applicable information for tests primarily performed in the POL setting. Finally, CMS rejected commenters' suggestions to permit voluntary reporting of applicable information from entities that do not qualify as applicable laboratories.

What must be collected and reported?

PAMA requires laboratories to report "applicable information," which includes information regarding private payor rates for a test and the volume of tests for each payor. If a laboratory has more than one payment rate from the same payor for a test or more than one payment rate from different payors for a test, all rates must be reported.

CMS finalized its proposal to define "applicable information" to also include the specific HCPCS code associated with each test. "Specific HCPCS code" excludes unlisted CPT codes and "not otherwise classified" (NOC) codes. In response to comments, CMS stated that it would list HCPCS codes for which applicable laboratories must report private payor rates on the CLFS website to clarify that only the specific codes on this list will need to be reported during the initial data collection period.

Importantly, CMS also clarified that laboratories are to only report "final payments" made during the data collection period for calculating the private payor weighted median rate. CMS clarified that private payor rates should include all final rates including non-contracted amounts paid to laboratories. CMS explained that claims under review by or appeal before the private payor are not deemed final and should not be reported. Additionally, private payor amounts for tests that are not correlated to a specific HCPCS code are not considered private payor rates for purposes of applicable information. Denied claims, or "zero payments," are also not included in applicable information under the Final Rule.

Further, the private payor rates to be reported are required to reflect all discounts, rebates and other price concessions, as well as any patient cost sharing amounts. CMS also made clear in the Final Rule that only private payor price concessions are included in the rate. As a result, any concessions by the laboratory, such as patient assistance programs, are not included.

When must data be collected and reported?

In the Final Rule, CMS elected to shorten the data collection period to six months in order to give laboratories a six-month window to ensure the completeness and accuracy of data. The data collection period is now from January 1 through June 30 for CDLTs with specific HCPCS codes. CMS stated in the Final Rule that it will re-evaluate the length of the data collection period in future rulemakings, including whether the 6 month review period before the reporting period is necessary. Laboratories must report the data to CMS by March 31, 2017. CMS will provide sub-regulatory guidance to specify the manner and form for reporting applicable information prior to the first reporting period. Although CMS will use NPI to determine an applicable laboratory, reporting will still be done by the TIN level entity.

B. Market-Based Payment Calculation

Under PAMA, the payment amount for a CDLT furnished on or after January 1, 2017 is the median of all private payor rates reported for each test weighted by volume for each private payor and each laboratory. CMS clarified that MACs would not be permitted to adjust the market based payment amounts.

PAMA limits the year over year reduction in payment amounts for a CDLT through 2022. In the Final Rule, CMS changed the payment reduction limitations to reflect the delay in implementation, setting the limitation at 10% of the national limitation amount (NLA) for 2018 through 2020 and 15% of the NLA for 2021through 2023. These limitations will not apply to new ADLTs or new CDLTs.

In response to comments, CMS clarified that the preliminary payment amounts for the CLFS published in September would reflect the full median private payor rate (without the phased-in reduction). The final rate published in November will only reflect the application of the phased-in payment reduction for the next calendar year.

To address concerns regarding transparency, CMS intends to release aggregate private payor rate and volume data, including the unweighted median rate, range of rates, and median and mean volume other than for tests provided by only a few laboratories or a single laboratory (such as for new ADLTs).

CMS also finalized its proposal to price tests without any applicable information reported by using crosswalking and gapfilling processes.

Advanced Diagnostic Laboratory Tests

PAMA creates a special payment category of "advanced diagnostic laboratory tests" that includes CDLTs covered under Part B that are offered and furnished only by a single laboratory and not sold for use by a laboratory other than the developing laboratory or a successor owner. To be an ADLT, a test must also meet detailed regulatory criteria for multiple biomarker tests (criterion A) or be FDA cleared or approved (criterion B). The Final Rule provides detailed guidance on the definition of an ADLT. Although PAMA allows the Secretary to establish similar criteria, CMS will not exercise that authority at this time.

A. Definition of ADLT

"Offered and furnished"

Under the Proposed Rule, CMS defined "offered and furnished" as requiring that an ADLT only be marketed and performed by a single laboratory. In response to comments, the Final Rule replaced the requirement that the test be "marketed and performed" with the statutory language "offered and furnished." CMS explained that this regulatory definition of single laboratory would not preclude a test that would otherwise qualify as an ADLT from being an ADLT simply because the single laboratory hires a third party to market the test. In that situation, the single laboratory would still be the entity expending the resources for the test.

Additionally, CMS rejected comments urging it to permit a test initially discovered by an academic institution and licensed to another entity for further development and commercialization to be eligible for ADLT status.

"Single laboratory"

CMS proposed to implement the "single laboratory" component of the definition by restricting ADLT status to laboratories with a single CLIA certificate. Commenters urged CMS to permit a test to be designated as an ADLT even if the offering laboratory has multiple CLIA certificates.

In the Final Rule, CMS agreed with commenters that requiring laboratories to administer all aspects of a test at a single location was "inconsistent with how laboratories are structured and how they operate." The Final Rule instead defines "single laboratory" as including the laboratory itself as well as entities that own or that are owned by the laboratory. All entities in the "single laboratory organization" may design, offer, and sell the test, but only the entities that are laboratories under CLIA may furnish the test.

"Multiple Biomarkers"

PAMA provides that to be designated an ADLT in the absence of FDA clearance or approval, a test must be an analysis of multiple biomarkers of DNA, RNA, or proteins combined with a unique algorithm to yield a single patient-specific result.

In the Proposed Rule, CMS had limited the definition of an ADLT to only molecular pathology tests that include an analysis of DNA or RNA. In the Final Rule, CMS reversed its position to make clear that ADLTs include tests based on an analysis of only proteins.

"Unique Algorithm"

Despite significant opposition from commenters and the CMS Advisory Panel, CMS finalized its proposal that to qualify for ADLT status under criterion A, a test must provide "new clinical diagnostic information" that cannot be obtained from any other test or combination of tests. CMS disagreed with the view that "unique algorithm" should only apply to the uniqueness of the algorithm itself and not to that of the patient-specific result, stating, among other things, that its requirement was necessary to prevent simple protein analyses from being considered ADLTs.

B. ADLT Designation Process

CMS will issue sub-regulatory guidance for laboratories on applying for ADLT status. Applicants submitting an application for designation under criterion A will be required to submit evidence of the empirically derived algorithm and show how a test provides new clinical diagnostic information that cannot be obtained from any other test or combination of tests. CMS plans to consider the recommendations of the CDLT Advisory Panel in determining ADLT status and assigning codes to ADLTs. CMS will consider quarterly application submission and review schedule when it promulgates sub-regulatory guidance.

CMS maintains that PAMA's confidentiality provisions do not cover information provided to the Secretary for purposes of ADLT determination. However, information might be protected from release in a Freedom of Information Act (FOIA) request if it qualifies as trade secrets or exempt commercial or financial information. Additionally, for tests designated as an ADLT, CMS will not release to the public applicable information, in aggregate or raw form. CMS will, however, provide the HCPCS code and CLFS rate associated with those tests, consistent with its current annual publication of the CLFS file.

C. Payment for new ADLTs

CMS rejected stakeholder suggestions to retain the 2017 implementation date required by statute for ADLTs, and will implement the actual list charge payment methodology for new ADLTs starting in 2018. The Final Rule defines new ADLTs as ADLTs for which payment has not been made under the CLFS prior to January 1, 2018.

Actual List Charge

PAMA requires that new ADLTs be paid based on the "actual list charge" for the laboratory test for an initial period of three quarters. The actual list charge is the publicly available rate on the first day on which the test is available for purchase by a patient covered by private insurance or is marketed to the public as a test a patient can receive (even if the test has not yet been performed). CMS defined "publicly available rate" as the lowest amount charged for an ADLT that is readily accessible. A laboratory seeking new ADLT status for a test must attest to the actual list charge in its application for ADLT status.

CMS proposed that the list charge payment begin on the first day of the calendar quarter after the date the test is first performed. In response to comments, CMS revised this proposal to commence the initial period on the first day of the calendar quarter immediately following the latter of the date the test is granted ADLT status and the date the test receives a coverage decision under Part B. This change will ensure that the new ADLT's three quarters at actual list charge start after the test is covered by Medicare. Between the triggering date and the beginning of the initial period, the payment amount for the test is determined by the MAC on the basis of information provided by the laboratory.

New ADLT reporting

PAMA requires that laboratories report applicable information for new ADLTs by the final day of the second quarter of the initial period to determine payment after the initial period. If no private payor data is reported for the test during this period, crosswalking and gapfilling will be used to determine the payment rate, as for other tests.


Under PAMA, if the Medicare payment amount for an ADLT during the initial period is more than 130% of what those payments would have been at the weighted median payment rate, CMS must recoup the difference. In the Final Rule, CMS recognized that its proposal to recoup the entire difference between actual list charge and weighted median would potentially thwart the statute's purpose of awarding special payment status to ADLTs. CMS adopted stakeholders' suggestions to only recoup the difference between the payment amount under the annual list charge and 130% of the payment amount under the weighted median. Further, the recoupment provision does not apply if no private payor data is reported during the initial period.

Payment for Existing ADLTs

PAMA requires that CMS publish payment rates for existing ADLTs and FDA cleared or approved tests by January 1, 2016. CMS extended this period to January 1, 2017, to reflect changes in the implementation timeline.

Commenters recommended that CMS use the existing MAC rates for existing ADLTs instead of gapfilling or crosswalking pricing methods. CMS disagreed, maintaining that this would not accomplish the statutory purpose of reflecting changes in market prices over time. Instead, CMS will use crosswalking and gapfilling to establish payment amounts for existing ADLTs. CMS is considering using a special identifier to indicate when a HCPCS code uniquely describes an existing test.

Payment for New CDLTs

CMS finalized its proposal to define a "new CDLT" as a CDLT that is assigned a new or substantially revised HCPCS code and which is not an ADLT. A "substantially revised HCPCS code" is a code for which there has been a substantive change to the definition of the test or procedure to which the code applies. For new CDLTs, CMS will determine payment rates using the existing crosswalking and gapfilling methodologies. New CDLTs would remain on this payment system until applicable information is reported for the CDLT and can be used to establish a payment amount under the weighted median methodology.


A. Coding for New Tests

CMS finalized its proposal to utilize the existing HCPCS coding process for new ADLTs and new FDA cleared or approved CDLTs. If tests in this category do not already have an assigned CPT or HCPCS Level II code, CMS will assign a temporary G code, which would be effective for up to two years, unless CMS believes it appropriate to continue to use that G code. CMS did not address the AMA CPT PLA proposal, but explained in the Final Rule that the agency will use HCPCS level I codes created and assigned by the CPT Editorial Panel for new tests on the CLFS whenever possible if they meet the agency's requirements for payment.

B. Unique Coding for Existing Tests

Under PAMA, by January 1, 2016, the Secretary must assign a unique HCPCS code and publicly report the payment rate for 1) each existing ADLT; and 2) each other existing CDLT that is cleared or approved by FDA and paid under Part B as of PAMA's enactment date. CMS interprets "unique" as a code that describes only a single test. As such, any new unique codes would be subject to the CLFS annual public meeting process.

Some commentators recommended that CMS not assign a unique code to tests if those tests already have a code that is being billed to Medicare. CMS maintains that the statute requires the statute requires CMS to assign a unique code for these tests. To alleviate stakeholder concerns CMS will not automatically assign a unique HCPCS code for an ADLT or other FDA-cleared or -approved test, and instead will allow laboratories to first indicate to the agency that its test requires a unique code.

C. Unique Identifiers on Request

PAMA requires that for tracking and monitoring purposes, if a laboratory or manufacturer requests a unique identifier for an ADLT or an FDA-cleared or approved laboratory test, CMS must utilize a means such as a HCPCS code or modifier to uniquely track the test. CMS finalized its proposal to utilize the existing HCPCS coding process to implement this requirement, meaning that if a laboratory or manufacturer specifically requests a unique identifier for tracking and monitoring an ADLT or other FDA-cleared or approved CDLT, CMS would assign the test a unique HCPCS code if it did not already have one.

Local Coverage Determinations (LCDs) and Designation of MACs

PAMA provides CMS with the authority to designate up to four MACs to establish LCDs and/or process Medicare claims for payment for CDLTs. Commenters were mixed on their support for consolidating LCD development and/or claims processing for CDLTs. CMS stated that they will give careful consideration to the input from stakeholders as the agency considers whether to downsize the number of MACs developing LCDs and/or processing claims for CDLTs. At this time CMS will not exercise this authority. In the interim, CMS instructed MACs to develop and implement CDLT-related LCDs in accordance with the guidance set forth in Chapter 13 of the Medicare Program Integrity Manual.


The PAMA market-based payment system was intended to provide predictability and transparency to the pricing system for clinical diagnostic laboratory tests. While the implementation delay until 2018 will allow additional time for CMS and stakeholders to transition to the new market-based payment reporting requirements, some provisions like payment for new ADLTs at actual list charge will not be available for new innovative laboratories in 2017. The implementation work for laboratories will likely be significant, and sub-regulatory guidance will provide critical information on for the form and manner of data reporting and the process for ADLT applications. Additionally, with roughly half of the states participating in the MolDX program, CMS will need to continue to consider whether to utilize its authority to consolidate LCD development for CDLTs in a smaller number of MACs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
25 Oct 2017, Webinar, Boston, United States

Foley Hoag will present a 60-minute webinar on Wednesday, October 25 at 12:30 pm EDT, offering guidance for in-house counsel regarding the basics of trademark and design protection in the European Union. Attendees will learn about the opportunities and pitfalls to be on the lookout for when looking to secure, protect, and enforce an IP portfolio overseas.

1 Nov 2017, Webinar, Boston, United States

Please join Foley Hoag on Wednesday, November 1, 2017 for a webinar that covers the details of drafting an appropriate arbitration clause for your company’s commercial contracts.

9 Nov 2017, Conference, Waltham, United States

Please join us on Thursday, November 9 at the Westin Waltham Hotel for our quarterly New England M&A Forum, which brings the latest in market trends and recent legal developments to the New England M&A professionals' community.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.